York scientists discover driving force behind prostate cancer
Scientists at the University of York have discovered the driving force behind the development of prostate cancer.
Mar 27, 2013
0
1
Scientists at the University of York have discovered the driving force behind the development of prostate cancer.
Mar 27, 2013
0
1
Multi-peptide vaccination therapy combined with the low-dose steroid drug dexamethasone shows promise in treating chemotherapy-naive castration resistant prostate cancer (CRPC) patients.
Mar 15, 2013
0
0
Men with low-risk prostate cancer who previously had to choose between aggressive treatment, with the potential for significant side effects, and active surveillance, with the risk of disease progression, may have a new option. ...
Mar 5, 2013
0
0
Not surprisingly, a cancer diagnosis creates stress. And patients with prostate cancer show higher levels of anxiety compared to other cancer patients.
Jan 25, 2013
0
1
(Medical Xpress)—A high-fiber diet may have the clinical potential to control the progression of prostate cancer in patients diagnosed in early stages of the disease.
Jan 9, 2013
0
0
Researchers at Mayo Clinic's campus in Florida have identified an enzyme specifically linked to aggressive prostate cancer, and have also developed a compound that inhibits the ability of this molecule to promote the metastatic ...
Dec 18, 2012
0
0
Prostate cancer presents a dilemma for patients and the physicians who treat them. Which cancers are essentially indolent and present no risk and which are life threatening? Which can be watched and which need aggressive ...
Nov 28, 2012
0
1
Cancer of the prostate – the most common male cancer in the UK – presents in two distinct ways: a low-risk type, which may never cause any symptoms, and a high-risk form that needs treatment to prevent it spreading to ...
Oct 29, 2012
0
0
Prostate cancer is one of the most common cancers in men and early treatment is usually very successful. However, like other cancers, obesity increases the risk of aggressive prostate disease. New research, published in BioMed ...
Sep 24, 2012
0
0
Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga) offers a significant survival benefit to patients with castration-resistant prostate cancer, ...
Sep 17, 2012
0
0